The market expects Regeneron (REGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

When examining Regeneron Pharmaceuticals in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent: Regeneron Pharmaceuticals is in a ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

The study featured a head-to-head comparison between Pfizer's drug and Dupixent, which is marketed by Sanofi (SNY 0.12%) and Regeneron (REGN-3.69%). Could Pfizer beat Sanofi and Regeneron in the ...

Data & APIs. Events. Premarket ...

Regeneron Pharmaceuticals, Inc.'s stock has dropped 30% since July due to concerns around Eylea's declining market share in the face of competition from generics and Roche's Vabysmo. Dupixent's ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) net income didn't rise as precipitously, it did improve, gaining 2% to $1 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company, which became of interest to me after a close friend tipped me off about their potential to enter the weight loss market ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday Skip to main content ...

Regeneron (REGN) closed the most recent trading day at $595.73, moving +1.54% from the previous trading session. This change lagged the S&P 500's 2.76% gain on the day. Meanwhile, the Dow gained 2 ...